During the study period, COVID-19 incidence inboth states was highest among unvaccinated persons without aprevious COVID-19 diagnosis compared with that among theother three groups. During the week beginning May 30, 2021,compared with COVID-19 case rates among unvaccinated persons without a previous COVID-19 diagnosis, COVID-19case rates were 19.9-fold (California) and 18.4-fold (New York)lower among vaccinated persons… Continue reading COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status andPrevious COVID-19 Diagnosis — California and New York, May–November 2021
Category: Infectivology
Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19
COVID-19 vaccine is the hope for containment of disease outbreak. The post vaccination adverse effect is an important consideration. The clot after vaccination is an emerging important clinical problem in some vaccine recipients.1 The cause of post vaccination blood clot is not known. It is proposed that the problem might be due to immunopathological process.2… Continue reading Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19
First time detection of the vaccine spike protein in a person who died after vaccination against Covid-19.
The suspicion that the spike protein formed in the body as a result of the "vaccination" against Covid-19 could be responsible for the pathologically observed inflammations and lesions of vessels has now been confirmed immunohistologically for the first time. The pathologists Prof. Dr. Arne Burkhardt and Prof. Dr. Walter Lang and their team have succeeded… Continue reading First time detection of the vaccine spike protein in a person who died after vaccination against Covid-19.
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
ORIGINAL ARTICLE PEER-REVIEWED Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city… Continue reading Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients?
On October 2020, Sestili and Fimognari reported that acetaminophen (N-aetyl-para-aminophenol), commonly known as paracetamol, induces or worsens glutathione (GSH) consumption in elderly patients affected by early or mild coronavirus disease 2019 (COVID-19), thus greatly enhancing the risk of COVID-19 exacerbation in these patients.1 By early COVID-19, we mean the typical or commonly acknowledged symptomatology associated… Continue reading Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients?
Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study
Robust evidence of whether vitamin D deficiency is associated with COVID-19 infection and its severity is still lacking. The aim of the study was to evaluate the association between vitamin D levels and the risks of SARS-CoV-2 infection and severe disease in those infected. A retrospective study was carried out among members of Clalit Health… Continue reading Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study
COVID-19 trends and severity among symptomatic children aged 0-17 years in ten EU countries, 3 August 2020 – 3 October 2021
To guide evidence-based prevention of COVID-19 in children, we estimated risks of severe outcomes in 820,404 symptomatic paediatric cases reported by 10 EU Member States between August 2020 and October 2021. Case and hospitalisation rates rose as overall transmission increased but severe outcomes were rare: 9,611 (1.2%) were hospitalised, 640 (0.08%) required intensive care and… Continue reading COVID-19 trends and severity among symptomatic children aged 0-17 years in ten EU countries, 3 August 2020 – 3 October 2021
Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries
Policy makers and mainstream news anchors have promised the public that the COVID-19 vaccine rollout worldwide would reduce symptoms, and thereby cases and deaths associated with COVID-19. While this vaccine rollout is still in progress, there is a large amount of public data available that permits an analysis of the effect of the vaccine rollout… Continue reading Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear. Methods We conducted a retrospective observational study comparing three groups: (1)SARS-CoV-2-naïve individuals who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, (2)previously infected individuals who have not been… Continue reading Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
2 Medical News 